US › Healthcare

Adicet Bio Inc (ACET)

US · Healthcare · Biotechnology

$9.01-0.44%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-21.4M

EPS

$-1.99

EPS estimate

$-2.43

EPS came in at -1.99 against a street estimate of -2.43 — a beat of 18.1%.

Key statistics

Market cap

$89.1M

Forward P/E

0.0

P/B

0.74

Book value

$11.16

EPS (TTM)

$-10.42

52-week high

$17.44

52-week low

$6.01

50-day MA

$8.80

200-day MA

$8.07

Beta

1.59

Analyst view

Analysts rate Adicet Bio Inc a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $33.17.

Shareholding

Insiders

1.08%

Institutions

64.70%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	12.63%
Orbimed Advisors LLC	10.98%
Franklin Templeton Inc	6.69%
Citadel Advisors Llc	4.62%
Vanguard Capital Management, LLC	3.59%
Woodline Partners LP	3.34%
Adage Capital Partners Gp LLC	2.93%
Renaissance Technologies Corp	2.48%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adicet Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.